Research in Practice in Cancer
Research in Practice in Cancer
Event
logo
 
Join us at 10am BST on the 21st April for the second episode in our four-part series on Cancer Research, with Dr Luke Tattersall from the University of Sheffield. In the period 7th April-29th April, Researcher Live will feature exclusive sessions on innovations and advancements in cancer research, spotlighting experts in the field. Sign up here to receive email updates about this series.
 
Programme:
 
  • 7th April, 10am BST - Prof Ann Ager, Cardiff University: 'T cell homing in cancer immunotherapy: challenges and opportunities'

 

  • 21st April, 10am BST - Dr Luke Tattersall, University of Sheffield: ‘Preclinical bone cancer research’

 

  •  27th April, 4pm BST - Prof Chris Bakal, Institute of Cancer Research: ‘The shape of you: Using AI, bioengineering, and statistical cell biology to understand how changes in cell morphogenesis drives cancer’

 

  • 29th April, 4pm BST- Prof Dean Fennell, University of Leicester: ‘Mesothelioma. The evolving treatment landscape and future directions’

 

In this second session, Dr Luke Tattersall will discuss the research focus of his lab. This includes high throughput drug screening, lead compound validation, and overcoming metastasis and chemotherapy resistance, with the goal of improving treatments and patient survival outcomes in the future.
 
Patients often have a poor 5-year survival rate of 20-30% with metastasis and brutal debilitating treatment regimens such as polychemotherapy, limb salvage surgery or amputation. This has not changed in the past 40 years, highlighting the need for novel therapeutics.
 

Dr Tattersall's presentation will include:

 

  • An overview of bone cancer.

 

  • An overview of bone cancer research techniques and preclinical models used in our lab group both in vitro and in vivo.

 

To speak at a Researcher Live session, please email kristine.lennie@researcher-app.com 

 

Follow the Researcher Live's 'Strides in Cancer Research' profile for updates on the series, by clicking here.

Date and Time
Thursday, April 21, 2022 9:00 AM 09:00 am - 10:00 am GMT+0
Speakers Avatar Dr Luke Tattersall, University of Sheffield

Dr Luke Tattersall graduated with a First Class honours degree in Biomedical Sciences with a year industrial placement in 2015. He completed his Bone Cancer Research Trust-funded PhD focusing on osteosarcoma research in 2019.

 

During his PhD, he received 3 awards from the Bone Research Society, carried out a travelling fellowship at the University of Ferrara Italy, spoke about bone cancer on TV and was an invited speaker at the International Purine meeting in Brazil. He has research experience with both in vitro and in vivo preclinical models of the disease. He is now a post-doctoral researcher and has continued to research bone cancers in the lab of Prof Allie Gartland. Prof Gartland and Dr Luke Tattersall are passionate about improving the lives of primary bone cancer patients with the development of new therapeutics. 

DOI: hJPAqkFy1EivcXMkoZMv_prepost_1

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.